Helicobacter pylori colonizes more than 50% of the world population thus, it is considered an important cause of gastric cancer.
INTRODUCTION
Helicobacter pylori is a motile, curved, Gram negative rod isolated for the first time in 1982 by Warren and Marshall (30) .
It has been recognized as the main bacterial agent of chronic gastritis and duodenal ulcer, affecting more than 50% the world population and almost 70% of the Latin American population (8, 11, 19, 20, 21, 24) .
Once acquired, H. pylori produces a persistent infection with inflammation and polymorphonuclear infiltration of gastric mucosa. Some patients can develop atrophic chronic gastritis, considered as a risk factor for further occurrence of adenocarcinoma and gastric lymphoma (20, 21) . For this reason, H. pylori has been considered as a Group I cancer biological agent (21) .
One of the important aspects to consider is the high resistance levels of H. pylori to antimicrobials agents commonly used for treatment of gastric mucosal infections, such as ampicillin, clarithromycin, tetracycline and metronidazole reported in Latin America (5, 20, 27, 29) . Like other bacteria, H. pylori can show variable behavior to antimicrobials agents in different geographical areas, depending on the locally used drugs (17, 27).
The objectives of this work were to determine (i) the isolation frequency of H. pylori in Southern Chile from patients with symptomatology compatible with gastritis or gastric ulcer, (ii) the associated demographic parameters (like gender, age and educational level) and their correlation with the infected patients and (iii) the susceptibility profiles of the isolated strains to antimicrobial drugs used in the eradication treatment.
MATERIAL AND METHODS
A total of 240 patients with a male-to-female ratio of 0.73 (102 males and 138 females), ranging from 11 to 86 years old The antimicrobials tested were amoxicillin, ciprofloxacin, clarithromycin, gentamicin, metronidazole. The breakpoints used to define the resistance were as follows: amoxicillin (>2 Isolation of H. pylori in gastric mucosa g/ml), ciprofloxacin (>4 g/ml), clarithromycin ( 2 g/ml), metronidazole (>8 g/ml) and tetracycline (4 g/ml) (5, 18, 27) .
RESULTS
Two hundred and forty biopsy simples were analyzed.
Ninety nine (41.3%) were positive for H. pylori. Isolation frequencies were higher among females (42%) than males (40.2%). However, this difference was not statistically significant (p >0.5). The highest isolation frequencies were obtained in patients from 21-30 years old (55%) and 41-50 (52.6%) years old (Table 1 ) and in patients with secondary (43.9 %) and university (46.2%) educational levels (data not shown).
Among the 88 strains studied, 19 (21.6%) showed simultaneous resistance to more than one antimicrobial drug.
MICs for metronidazole varied from <0.016 to >256 µg/ml with 12.5% of resistance. This antimicrobial drug showed the lowest activity (Table 2) .
No resistance was found for tetracycline whose CIMs ranged from <0.016 to 0.75 µg/ml (Table 2) . CIMs ranges for the other four drugs were: < 0.0012 to >32 µg/ for ciprofloxacin, <0.016 to 64 µg/ml for clarithromycin, <0.016 to >256 µg/ml for amoxicillin and <0.016 to >256 for metronidazole.
The most frequently resistance patterns found were: i. (11, 12, 19, 21, 24) . Previous studies in Chile, reported isolation frequencies ranging from 60 to 70% in adults (28) . In this study, however, we found a lower isolation frequency (41.3%). The differences observed among Chilean studies could be due to the use of different diagnostic methods American countries (11, 15, 22, 23) .
Nineteen (21.6%) strains showed resistance to at least one antimicrobial drug. As shown in Table 2 , two strains (2, 3%)
were resistant to amoxicillin. Metronidazole showed the lowest activity with 11 (12.5%) This antibiotic has been used together with furazolidone to treat H. pylori infection in Brazil, China and Peru, due to their low cost and to the resistance to metronidazole and macrolides found in those countries (2).
RESISTANCE PROFILES
Five strains (5.7%) were resistant to ciprofloxacin. This finding agrees with data reported by Toro et al (26) in Spain (7.9%) and Glocker et al (9) in Germany (9.5%). The highest resistance frequency to ciprofloxacin (21%) has been reported in Portugal (17).
Simultaneous resistance was observed in six strains. Five were simultaneously resistant to metronidazole and clarithromycin and one to amoxicillin, clarithromycin and metronidazole. Since these antimicrobials are the most frequently recommended in H. pylori eradication treatments, these findings highlight an urgent need to establish a resistance surveillance system in order to prevent treatment failures and the spread of resistant strains. In addition, it is important to establish whether these resistant strains represent sporadic cases or correspond to an usual resistance behavior in a given geographic region. 
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